Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
阿卡地新制备储备液:
浓度溶解体积质量
1mg
5mg
10mg
1mM
2.1032mL
10.5159mL
21.0318mL
5mM
0.4206mL
2.1032mL
4.2064mL
10mM
0.2103mL
1.0516mL
2.1032mL
50mM
0.0421mL
0.2103mL
0.4206mL
阿卡地新临床数据( 数据源于:http:// clinicaltrials.gov)
Conversion of different model animals based on BSA(Value based on data from FDA Draft Guidelines)
Animal A (mg/kg)=Animal B(mg/kg)multiplied by AnimalBm系数/AnimalAm系数 For example, to modify the dose of resveratrol uesd for a mouse(22.4mg/kg) to a dose based on the BSA for a rat, multiply 22.4mg/kg by the Km factor for a mouse and zhen divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2mg/kg